M
Mayer B. Davidson
Researcher at Charles R. Drew University of Medicine and Science
Publications - 252
Citations - 21085
Mayer B. Davidson is an academic researcher from Charles R. Drew University of Medicine and Science. The author has contributed to research in topics: Diabetes mellitus & Insulin. The author has an hindex of 49, co-authored 243 publications receiving 20333 citations. Previous affiliations of Mayer B. Davidson include Cleveland Clinic & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan,John B. Buse,Mayer B. Davidson,Ele Ferrannini,Rury R. Holman,Robert S. Sherwin,Bernard Zinman +6 more
TL;DR: This revision of the consensus algorithm for the medical management of type 2 diabetes focuses on the new classes of medications that now have more clinical data and experience and addresses safety issues surrounding the thiazolidinediones.
Journal ArticleDOI
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
David M. Nathan,Beverly Balkau,Enzo Bonora,Knut Borch-Johnsen,John B. Buse,Stephen Colagiuri,Mayer B. Davidson,Ralph A. DeFronzo,Saul Genuth,Rury R. Holman,Linong Ji,Sue Kirkman,William C. Knowler,Desmond A. Schatz,Jonathan E. Shaw,Eugene Sobngwi,Michael Steffes,Olga Vaccaro,Nicholas J. Wareham,Bernard Zinman,Richard Kahn +20 more
TL;DR: Kilpatrick et al. as mentioned in this paper discussed the limitations of the A1C assay for populations in which it is not available or is currently too expensive, as well as for individuals in whom the assay may be misleading.
International expert committee report on the role of the A1C assay in the diagnosis of diabetes
David M. Nathan,Beverly Balkau,Enzo Bonora,Knut Borch-Johnsen,John B. Buse,Stephen Colagiuri,Mayer B. Davidson,Ralph A. DeFronzo,Saul Genuth,Rury R. Holman,Linong Ji,Sue Kirkman,William C. Knowler,Desmond A. Schatz,Jonathan E. Shaw,Eugene Sobngwi,Michael Steffes,Olga Vaccaro,Nicholas J. Wareham,Bernard Zinman,Richard Kahn +20 more
TL;DR: Members of the International Expert Committee have recommended that diabetes should be diagnosed if A1C is ≤6.5%, without need to measure the plasma glucose concentration, but there are concerns that practical limitations will lead to false positives and negatives with this approach.
Journal ArticleDOI
Impaired fasting glucose and impaired glucose tolerance: implications for care.
David M. Nathan,Mayer B. Davidson,Ralph A. DeFronzo,Robert J. Heine,Robert R. Henry,Richard E. Pratley,Bernard Zinman +6 more
TL;DR: With the development of diabetes, there is a large increase in risk for CVD, as well as for long-term complications affecting the eyes, kidneys, and nervous system, and the risk of a CVD event is modestly increased.
Journal ArticleDOI
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
David M. Nathan,John B. Buse,Mayer B. Davidson,Robert J. Heine,Rury R. Holman,Robert S. Sherwin,Bernard Zinman +6 more
TL;DR: The development of new classes of blood glucose–lowering medications to supplement the older therapies, such as lifestyle-directed interventions, insulin, sulfonylureas, and metformin, has increased the treatment options for type 2 diabetes.